Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide
Publishing timestamp: 2024-05-03 13:43:34
Summary
Amgen's stock rose after teasing positive initial data on its weight loss injection, causing concerns for Novo Nordisk and Eli Lilly. Amgen's CEO expressed confidence in the drug's potential and highlighted competitive advantages. Novo Nordisk struggled with sales of its weight loss injection, while Eli Lilly reassured investors about overcoming supply constraints for its popular drugs.
Sentiment: MIXED
Tickers: AMGN, NOVO.B-DK, LLY, NVO,
Keywords: novo nordisk a/s, business news, biotechnology, health care industry, amgen inc, business, pharmaceuticals, biotech and pharmaceuticals, eli lilly and co,